Tottenham Hotspur Announces Ant International as Global Payment Solutions and Digital Wallet Partner
12.9.2024 15:07:00 CEST | Business Wire | Press release
Club announces strategic partnership with Ant International, a global leader in digital payment and financial technologyThe partnership, which incorporates associated brands Alipay+, WorldFirst and Antom, will see Ant International become the Club’s exclusive Official Global Payment Solutions and Digital Wallet Partner and Alipay+ the first Official Training Wear Sleeve Partner for both the men’s and women’s teamsAnt International will be working with the Club to support growth of and increase engagement with our supporters across the Asia-Pacific region
Tottenham Hotspur has today announced a new three-year strategic partnership with Ant International, a digital payment and financial technology leader.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912483736/en/
Scott Munn (left), Chief Football Officer, Tottenham Hotspur and Yang Peng, Chief Executive Officer, Ant International signed a three-year strategic partnership on Thursday. (Photo: Business Wire)
The partnership sees Ant International, together with its business brands Alipay+, Antom and WorldFirst, become the exclusive Official Global Payment Solutions and Digital Wallet Partner of Tottenham Hotspur, and Alipay+ the first Official Training Wear Sleeve Partner for both the men’s and women’s teams.
The Club will be working with Ant International, through its digital technology solutions brand Alipay+ and merchant payment services brand Antom, to provide a seamless payment experience for fans at our Stadium and on e-commerce platforms, using payment methods widely used in the Asia-Pacific (APAC) region.
Ant International will also support the Club on activations to drive growth of and engagement with our fanbase in the APAC region via its partner digital payment apps, including Alipay. Ant International has a rich portfolio of experience in driving digital engagement through football, having sponsored both the UEFA Euro 2020 and 2024 tournaments.
Yang Peng, Chief Executive Officer, Ant International said: “Football is a game that can be enjoyed by everyone and has the power to transcend borders, bringing people together. This aligns with Ant International’s mission in our globalization – leveraging technological innovation to provide individuals and small businesses with greater access to inclusive financial services.
Tottenham Hotspur has the forward-looking vision of leveraging cutting-edge technologies to enhance fan experience. We resonate with the Club’s ‘To Dare is To Do’ spirit and look forward to working closely with Tottenham Hotspur to engage with its global fanbase through our innovative payment and digitalisation solutions, inspiring the 1.6 billion consumers served by Alipay+ and its partners through the sport and the Club.”
Daniel Levy, Chairman, Tottenham Hotspur said: “The Club and Ant International are fully aligned as we look to deepen connections with our football fans through digital interactions. We shall also be supporting the growth in awareness of the Ant International brand across our extensive global platforms as an elite Premier League Club.
Ant International, together with its ecosystem associates, brings a wealth of experience in digital fan engagement in football following its partnerships during the two most recent UEFA European championships. We are excited to work with them to enhance the digital experience for our fans in-Stadium and online - and further engage our fanbase across the APAC region.”
About Ant International
Headquartered in Singapore, Ant International powers the future of global commerce with digital innovation for everyone and every business to thrive. In close collaboration with partners, we support merchants of all sizes worldwide to realize their growth aspirations through a comprehensive range of tech-driven digital payment and financial services solutions.
About Alipay+
Alipay+ is a suite of cross-border mobile payment and digitalisation technology solutions that help connect global merchants to consumers. Consumers enjoy seamless payment and a broad choice of deals using their preferred payment methods while travelling abroad. Small and medium-sized businesses may use Alipay+ digital tools to enhance efficiency and achieve omni-channel growth.
About Antom
Antom is a leading provider of payment and digitisation services to merchants worldwide. Antom provides one-stop, vertical-specific digital payment solutions to meet the payment needs for merchants of all sizes, especially SMEs. With a presence in over 150 markets, Antom currently supports merchants in over 40 markets with the flexibility to accept payments in more than 100 currencies. Antom also provides digital marketing solutions and merchant digitisation services to help merchant in digital operations and to better engage with their customers.
About WorldFirst
WorldFirst is a one-stop digital payment and financial services platform for global businesses, especially SMEs in international trade. WorldFirst, which employs AI and other cutting-edge technologies for risk control, prioritises the safety and security of client funds above all else and has a leading fraud-prevention track record in the industry. WorldFirst has served one million customers worldwide and is connected to over 120 marketplaces. WorldFirst was founded in 2004 and joined Ant Group in 2019.
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912483736/en/
Contacts
Media Inquiries
Media Inquiries
Ant International
Fanny Wu
chen.wc@antgroup.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom